The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Gilead Sciences has been a relatively solid performer this year in the biotech sector as its peers have struggled. The stock is up nearly 15% year-to-date, lagging the S&P 500. Yet it's rebounded 35% ...